ArticleAddiction (Abingdon, England)2020
Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Article in Addiction (Abingdon, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 74 citations in OpenAlex.
- Long-Acting Injectable Buprenorphine in Prison: Insights From a Short-Answer Survey of People in the Criminal Justice System Commencing Long-Acting Injectable Buprenorphine During a Non-Randomised Clinical Trial.Drug and alcohol review · 2026Article
- Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey.Drug and alcohol review · 2026Article
- Article
- Changing patterns of opioid agonist therapy prescribing in a network of specialised clinics providing care to people with opioid use disorder in Victoria, Australia, 2015 to 2023.Drug and alcohol review · 2025Article
- Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).Contemporary clinical trials · 2025Article
- Article
- Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.Drug and alcohol review · 2025Article
- Community-level factors influencing the duration of buprenorphine treatment in individuals with opioid use disorder: a cohort study using US longitudinal claims data.BMJ public health · 2025Article
- "You might be nice, but where you take me, they're not gonna be": Preferences for field-based post-overdose interventions.Drug and alcohol review · 2024Article
- Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study.Journal of substance use and addiction treatment · 2024Article
- The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review.Campbell systematic reviews · 2024Review
- Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study.Addiction science & clinical practice · 2024Article
- Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.Journal of viral hepatitis · 2024Article
- Patients' goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study.Substance abuse treatment, prevention, and policy · 2023Article
- Incidence of suicide and self-harm among people with opioid use disorder and the impact of opioid agonist treatment: A retrospective data linkage study.Drug and alcohol dependence · 2023Article
- Taking a chance: How likely am I to receive my preferred treatment in a clinical trial?Statistical methods in medical research · 2023Article
- Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study.Substance abuse treatment, prevention, and policy · 2022Article
- Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.Drug and alcohol review · 2022Article
- Article
- Buprenorphine and its formulations: a comprehensive review.Health psychology research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
aimsTo examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia.
designCross-sectional survey prior to implementation. XR-buprenorphine was registered in Australia in November 2018.
settingSydney, Melbourne and Hobart. Participants A total of 402 people who regularly use opioids interviewed December 2017 to March 2018. MEASUREMENTS: Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthly injections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosing setting, unsupervised doses, out-of-pocket expenses and travel distance).
findingsSixty-eight per cent [95% confidence interval (CI) = 63-73%] believed XR-buprenorphine was a good treatment option for them. They were more likely to report being younger [26-35 versus > 55 years; odds ratio (OR) = 3.16, 95% CI = 1.12-8.89; P = 0.029], being female (OR = 1.67, 95% CI = 1.04-2.69; P = 0.034), < 10 years school education (OR = 1.87, 95% CI = 1.12-3.12; P = 0.016) and past-month heroin (OR = 1.81, 95% CI = 1.15-2.85; P = 0.006) and methamphetamine use (OR = 1.90, 95% CI = 1.20-3.01; P = 0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% preferred weekly and 39% preferred monthly. Among OAT recipients (n = 255), believing XR-buprenorphine was a good treatment option was associated with shorter treatment episodes (1-2 versus ≥ 2 years; OR = 3.93, 95% CI = 1.26-12.22; P = 0.018), fewer unsupervised doses (≤ 8 doses past-month versus no take-aways; OR = 0.50; 95% CI = 0.27-0.93; P = 0.028) and longer travel distance (≥ 5 versus < 5 km; OR = 2.10, 95% CI = 1.20-3.65; P = 0.009). Sixty-nine per cent reported 'no problems or concerns' with potential differences in availability, flexibility and location of XR-buprenorphine.
conclusionsAmong regular opioid users in Australia, perceptions of extended-release buprenorphine as a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)convenience of current opioid agonist treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.